Login to Your Account



No IPO? No Problem

Helix Takes Road Less Traveled to Reach U.S. Capital Markets

By Jennifer Boggs


Monday, March 21, 2011
Last week, HIV drug developer Koronis Pharmaceuticals Inc. said it was exploring a range of financing options, including a possible listing on London's AIM exchange, to access adequate funding for mid- and late-stage activities. But one alternative the Seattle-based firm won't be considering is a traditional initial public offering (IPO) on Nasdaq.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription